SLS

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies. The company focuses on therapies targeting acute myeloid leukemia and other blood cancers. Its lead product candidate is galinpepimut-S, a cancer immunotherapy designed to stimulate immune responses against malignant cells.